Skip to main content

Table 2 Infection characteristics and antibiotic treatmenta

From: Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

  Excluded from randomized controlled trial (N = 295) Included in randomized controlled trial (N = 406) P value
Infection characteristics
 Acquisition of infection in the intensive care unit 67 (22.7%) 124 (30.5%) 0.022
 Pathogen
  Acinetobacter baumannii 236 (80%) 312 (76.8%) 0.318
  Enterobacterales 35 (11.9%) 73 (18%) 0.027
  Pseudomonas/other 24 (8.1%) 21 (5.2%) 0.114
 Type of infection
  Bacteraemia 109 (36.9%) 173 (42.6%) 0.131
  Ventilator-associated or hospital-acquired pneumonia 140 (47.5%) 182 (44.8%) 0.490
  Probable ventilator-associated pneumonia 14 (4.7%) 25 (6.2%) 0.421
  Urinary tract infection 32 (10.8%) 26 (6.4%) 0.035
 Colistin MIC distribution > 0.5 mg/L 18 (7.7%), n = 233 85 (24.3%), n = 350 0.000
Antibiotic treatment    0.000
 Colistin 113 (68.1%), n = 166 198 (48.8%)  
 Colistin and meropenem 53 (31.9%), n = 166 208 (51.2%)  
 Colistin loading dose 122 (73.5%), n = 166 376 (92.6%) 0.000
 Treatment days in patients alive ≥14 days, median (Percentiles 25–75) 8.5 (0–15), n = 200 13 (10–16), n = 273 0.000
Mean colistin maintenance dose per day, million units (percentiles 25–75)
 Creatinine clearance< 50 ml/min 4.2 (2.1–6.0) 4.0 (3.0–6.0) 0.629
 Creatinine clearance≥50 ml/min 8.6 (5.8–9.0) 8.5 (7.0–9.0) 0.239
  1. aNumbers apply to all patients in the group unless stated otherwise
\